網膜障害治療の市場規模、シェア、成長分析、タイプ別、調剤別、流通チャネル別、地域別 - 産業予測 2025-2032年

網膜障害治療市場規模は2023年に119億2,000万米ドルとなり、予測期間（2025-2032年）のCAGRは9.45%で、2024年の130億5,000万米ドルから2032年には268億7,000万米ドルに成長する見通しです。

世界の網膜障害治療市場は、人口の高齢化と糖尿病率の上昇を主因とする加齢黄斑変性（AMD）や糖尿病性網膜症などの疾患の有病率の増加により、急速に発展しています。未治療の網膜疾患は視力障害や失明のリスクをもたらすため、効果的な治療に対する需要が急増しています。主な技術革新には、湿性AMDや糖尿病網膜症の管理を一変させたルセンティスやエイレアなどの抗VEGF療法があります。さらに、遺伝子治療や幹細胞治療の進歩は、遺伝性疾患に対する長期的な解決策として有望です。強化された網膜画像技術は、早期診断と個別化治療を促進しています。しかし、高額な治療費や規制上のハードルといった課題は依然として残っています。研究開発の進展に伴い、市場は継続的な成長を遂げ、最終的には患者の転帰と生活の質の向上につながるものと思われます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制分析

網膜障害治療市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 黄斑変性症
  • 乾性黄斑変性症
  • 湿性黄斑変性症
• 糖尿病網膜症
• その他

網膜障害治療市場規模：調剤別& CAGR（2025-2032）

• 市場概要
• ゲル
• アイソリューションズ
• カプセルと錠剤
• 目薬
• 軟膏

網膜障害治療市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• オンライン薬局
• 小売薬局

網膜障害治療市場規模& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Regeneron Pharmaceuticals, Inc.（USA）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• AbbVie Inc.（USA）
• Pfizer, Inc.（USA）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Takeda Pharmaceutical Company Limited（Japan）
• Alcon Inc.（Switzerland）
• Bausch Health Companies Inc.（Canada）
• Merck & Co., Inc.（USA）
• Biogen Inc.（USA）
• Alimera Sciences, Inc.（USA）
• Graybug Vision, Inc.（USA）
• Kubota Pharmaceutical Holdings Co., Ltd.（Japan）
• Allergan plc（Ireland）（Now part of Abbvie）
• Ophthotech Corporation（USA）
• Genentech（USA）（Part of Roche）
• EyeBio（USA）（Acquired by Merck）
• Carl Zeiss Meditec AG（Germany）

結論と提言

Retinal Disorder Treatment Market size was valued at USD 11.92 billion in 2023 and is poised to grow from USD 13.05 billion in 2024 to USD 26.87 billion by 2032, growing at a CAGR of 9.45% during the forecast period (2025-2032).

The global retinal disorder treatment market is rapidly evolving, driven by the increasing prevalence of conditions like age-related macular degeneration (AMD) and diabetic retinopathy, largely due to aging populations and rising diabetes rates. With untreated retinal disorders posing risks of vision impairment and blindness, demand for effective treatments is surging. Key innovations include anti-VEGF therapies, such as Lucentis and Eylea, which have transformed wet AMD and diabetic retinopathy management. Additionally, advancements in gene and stem cell therapies offer promising long-term solutions for inherited disorders. Enhanced retinal imaging technologies are facilitating earlier diagnosis and personalized treatments. However, challenges such as high treatment costs and regulatory hurdles persist. As R&D efforts progress, the market is poised for continued growth, ultimately improving patient outcomes and quality of life.

Top-down and bottom-up approaches were used to estimate and validate the size of the Retinal Disorder Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Retinal Disorder Treatment Market Segments Analysis

Global Retinal Disorder Treatment Market is segmented by Type, Dosage, Distribution Channel and region. Based on Type, the market is segmented into Macular Degeneration, Diabetic Retinopathy and Others. Based on Dosage, the market is segmented into Gels, Eye Solutions, Capsules & Tablets, Eye Drops and Ointments. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Retinal Disorder Treatment Market

The growing aging population serves as a major catalyst for the retinal disorder treatment market. As individuals age, their risk of developing a range of eye conditions, such as age-related macular degeneration (AMD) and diabetic retinopathy, significantly increases. With the global elderly demographic expanding, a corresponding rise in the incidence of retinal disorders is anticipated, which will consequently boost the demand for effective treatments and therapies for these conditions. This demographic trend underscores the urgency for advancements in the treatment of retinal disorders, thereby shaping the market dynamics and influencing healthcare strategies aimed at addressing these age-related eye issues.

Restraints in the Retinal Disorder Treatment Market

The retinal disorder treatment market faces notable constraints primarily due to the high costs associated with various treatment options. Many therapies, such as anti-VEGF solutions and surgical interventions, come with considerable expenses that may hinder patient access. This financial burden is particularly impactful in areas with limited healthcare resources or where insurance coverage is inadequate, ultimately restricting the availability of necessary treatments for patients in need. Consequently, these economic barriers can impede the overall growth and development of the retinal disorder treatment market, as a significant portion of the population may remain untreated or under-treated.

Market Trends of the Retinal Disorder Treatment Market

The Retinal Disorder Treatment market is witnessing a notable trend characterized by significant advancements in retinal imaging and diagnostic technologies. Innovations such as optical coherence tomography (OCT) and adaptive optics have revolutionized early detection of retinal disorders, allowing for timely interventions that mitigate potential vision loss. Furthermore, the incorporation of artificial intelligence (AI) and machine learning into imaging processes has increased diagnostic accuracy and efficiency, enabling healthcare providers to make more informed treatment decisions. This shift towards early diagnosis and AI-driven diagnostics not only enhances patient outcomes but also drives demand in the retinal treatment landscape, securing a robust growth trajectory for the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Retinal Disorder Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Macular Degeneration
  • Dry Macular Degeneration
  • Wet Macular Degeneration
• Diabetic Retinopathy
• Others

Global Retinal Disorder Treatment Market Size by Dosage & CAGR (2025-2032)

• Market Overview
• Gels
• Eye Solutions
• Capsules & Tablets
• Eye Drops
• Ointments

Global Retinal Disorder Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Retinal Disorder Treatment Market Size & CAGR (2025-2032)

• North America (Type, Dosage, Distribution Channel)
  • US
  • Canada
• Europe (Type, Dosage, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Dosage, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Dosage, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Dosage, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alimera Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kubota Pharmaceutical Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)(Now part of Abbvie)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ophthotech Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech (USA)(Part of Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyeBio (USA)(Acquired by Merck)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carl Zeiss Meditec AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations